Compare Stocks: ARTL, ADXN, PCSA, and NCNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.79 +1.5%	$5.88	$5.04 ▼ $12.05	$7.02M	1.5	983 shs	406 shs
ARTL Artelo Biosciences	$0.72 -1.4%	$1.01	$0.69 ▼ $30.00	$1.70M	-0.07	503,692 shs	196,681 shs
NCNA NuCana	$1.55 +2.0%	$1.48	$1.21 ▼ $7.22	$6.33M	2.25	34,678 shs	26,675 shs
PCSA Heatwurx	$2.15 +2.4%	$2.22	$1.67 ▼ $14.24	$5.81M	0.99	645,927 shs	25,072 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+2.41%	-4.30%	-3.99%	-19.10%	-30.67%
ARTL Artelo Biosciences	+1.23%	-1.99%	-36.53%	-48.60%	-97.51%
NCNA NuCana	-1.94%	+5.56%	+15.59%	-25.49%	-60.72%
PCSA Heatwurx	-1.41%	-20.15%	-9.09%	-19.54%	-61.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.79 +1.5%	$5.88	$5.04 ▼ $12.05	$7.02M	1.5	983 shs	406 shs
ARTL Artelo Biosciences	$0.72 -1.4%	$1.01	$0.69 ▼ $30.00	$1.70M	-0.07	503,692 shs	196,681 shs
NCNA NuCana	$1.55 +2.0%	$1.48	$1.21 ▼ $7.22	$6.33M	2.25	34,678 shs	26,675 shs
PCSA Heatwurx	$2.15 +2.4%	$2.22	$1.67 ▼ $14.24	$5.81M	0.99	645,927 shs	25,072 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+2.41%	-4.30%	-3.99%	-19.10%	-30.67%
ARTL Artelo Biosciences	+1.23%	-1.99%	-36.53%	-48.60%	-97.51%
NCNA NuCana	-1.94%	+5.56%	+15.59%	-25.49%	-60.72%
PCSA Heatwurx	-1.41%	-20.15%	-9.09%	-19.54%	-61.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
ARTL Artelo Biosciences	1.67	Reduce	$54.00	7,400.00% Upside
NCNA NuCana	1.00	Sell	N/A	N/A
PCSA Heatwurx	2.00	Hold	$25.00	1,062.79% Upside

Current Analyst Ratings Breakdown

Latest ARTL, ADXN, PCSA, and NCNA Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/17/2026	NCNA NuCana	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PCSA Heatwurx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	ARTL Artelo Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$210K	33.88	N/A	N/A	$4.67 per share	1.24
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	$2.14 per share	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	$6.53 per share	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	$2.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-134.76%	-106.00%	8/24/2026 (Estimated)
ARTL Artelo Biosciences	-$12.88M	-$32.74	N/A	N/A	N/A	N/A	-518.27%	-194.29%	N/A
NCNA NuCana	-$38.71M	-$3.81	N/A	N/A	N/A	N/A	-41.90%	-33.69%	N/A
PCSA Heatwurx	-$13.56M	-$4.23	N/A	N/A	N/A	N/A	-288.97%	-202.40%	10/29/2026 (Estimated)

Latest ARTL, ADXN, PCSA, and NCNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	PCSA Heatwurx	-$1.00	-$1.19	-$0.19	-$1.19	N/A	N/A
8/13/2026	Q2 2026	NCNA NuCana	-$2.6514	-$0.99	+$1.6614	N/A	N/A	N/A
8/12/2026	Q2 2026	ARTL Artelo Biosciences	-$0.72	-$0.89	-$0.17	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.97	0.97
ARTL Artelo Biosciences	N/A	3.00	3.00
NCNA NuCana	N/A	4.73	4.73
PCSA Heatwurx	N/A	0.98	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
ARTL Artelo Biosciences	0.87%
NCNA NuCana	44.00%
PCSA Heatwurx	91.93%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
ARTL Artelo Biosciences	3.20%
NCNA NuCana	31.20%
PCSA Heatwurx	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.23 million	1.05 million	Not Optionable
ARTL Artelo Biosciences	5	2.33 million	2.26 million	Not Optionable
NCNA NuCana	30	4.16 million	2.86 million	Not Optionable
PCSA Heatwurx	20	2.77 million	2.67 million	Not Optionable

ARTL, ADXN, PCSA, and NCNA Headlines

Recent News About These Companies

Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript

July 29, 2026 | seekingalpha.com

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.

July 29, 2026 | globenewswire.com

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026 | globenewswire.com

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

January 5, 2026 | globenewswire.com

PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

December 18, 2025 | zacks.com

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

December 17, 2025 | globenewswire.com

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

November 5, 2025 | globenewswire.com

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

August 7, 2025 | globenewswire.com

Processa Pharmaceuticals Provides Portfolio and Business Update

July 1, 2025 | globenewswire.com

Processa Pares Gains on Equity Offer News

June 17, 2025 | marketwatch.com

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

June 17, 2025 | globenewswire.com

Processa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for Gastroparesis

June 17, 2025 | quiverquant.comQ

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

June 17, 2025 | globenewswire.com

Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention

June 15, 2025 | nasdaq.com

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

June 13, 2025 | globenewswire.com

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025 | globenewswire.com

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025 | markets.businessinsider.com

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025 | globenewswire.com

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

March 18, 2025 | globenewswire.com

Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently

February 21, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARTL, ADXN, PCSA, and NCNA Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$5.78 +0.09 (+1.49%)

Closing price 02:55 PM Eastern

Extended Trading

$5.57 -0.21 (-3.68%)

As of 04:04 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Artelo Biosciences NASDAQ:ARTL

$0.72 -0.01 (-1.36%)

Closing price 04:00 PM Eastern

Extended Trading

$0.72 0.00 (0.00%)

As of 07:56 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

NuCana NASDAQ:NCNA

$1.55 +0.03 (+1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.55 0.00 (-0.26%)

As of 07:51 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Heatwurx NASDAQ:PCSA

$2.15 +0.05 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.13 -0.02 (-0.93%)

As of 07:30 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, ADXN, PCSA, and NCNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, ADXN, PCSA, and NCNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, ADXN, PCSA, and NCNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTL, ADXN, PCSA, and NCNA Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Artelo Biosciences NASDAQ:ARTL

NuCana NASDAQ:NCNA

Heatwurx NASDAQ:PCSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, ADXN, PCSA, and NCNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, ADXN, PCSA, and NCNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, ADXN, PCSA, and NCNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTL, ADXN, PCSA, and NCNA Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Artelo Biosciences NASDAQ:ARTL

NuCana NASDAQ:NCNA

Heatwurx NASDAQ:PCSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools